Metraipolis › archive › dc_54dc57dfea76

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study — Europe PMC PMID:41024110

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41024110
DOI
10.1186/s13058-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-11-09T17:16:44.915Z
SHA-256 of the archived text
3906bb9025d3ffb1944eb9d431402a495744b500a53c70e310ca9aa7a973e3ca
Stable URL of this page
https://metraipolis.com/documento/dc_54dc57dfea76

How to cite

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study — Europe PMC PMID:41024110 — Europe PMC (en), https://europepmc.org/article/MED/41024110 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_54dc57dfea76 (Metraipolis archive dc_54dc57dfea76, sha256 3906bb9025d3ffb1944eb9d431402a495744b500a53c70e310ca9aa7a973e3ca)
BibTeX
@misc{dc54dc57dfea76,
  title = {Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study — Europe PMC PMID:41024110},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41024110},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_54dc57dfea76; sha256 3906bb9025d3ffb1944eb9d431402a495744b500a53c70e310ca9aa7a973e3ca},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41024110. Agents can read the archived copy with the MCP tool read_document.